LEARN ABOUT MRI

MRI for Pancreatic Cancer Detection

Pancreatic cancer is considered one of the most aggressive and deadly forms of cancer. However, early detection though MRI and timely treatment can improve outcomes. In this article, explore the uses, procedures, and costs of MRI screening for pancreatic cancer.

Pancreatic cancer is often symptomless until it reaches advanced stages (III-IV), making early diagnosis rare and prognosis poor. In the UK, fewer than 10 per cent of patients are eligible for potentially curative surgery at diagnosis, and overall five-year survival remains below 7 per cent1,2. However, if a tumour is detected when it is 2 cm or smaller and surgery is possible, five-year survival can increase dramatically to over 40 per cent.

Advanced imaging, particularly MRI combined with MRCP (magnetic resonance cholangiopancreatography) and diffusion-weighted techniques, offers a crucial advantage in early detection3. It demonstrates high sensitivity and accuracy in detecting pancreatic tumours, comparable to computed tomography4.

Early MRI-based detection also enables the identification of precursor lesions, such as high-risk intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms5. Resection of these lesions before they become invasive provides a unique opportunity to prevent pancreatic cancer altogether, highlighting the critical role of advanced imaging in improving outcomes for UK patients.

Learn more about MRI for cancer detection here.

Why You Might Need a Pancreas MRI

There are several reasons why a pancreas MRI might be ordered, including:

Unexplained Symptoms

  • Persistent upper-abdominal pain, unexplained weight loss, new-onset diabetes after age 50, or painless jaundice can all be early warning signs of pancreatic disease, including cancer or chronic pancreatitis6–8
  • MRI is particularly useful when these symptoms are present, but other tests (like bloodwork or ultrasound) are inconclusive.

Abnormal Findings on an Ultrasound or CT

  • If an ultrasound or CT scan shows abnormalities, such as a dilated “double duct” (enlargement of both the bile and pancreatic ducts), a pancreas MRI can provide high-contrast, soft-tissue detail to clarify the nature of the abnormality and guide further management9.

Family or Genetic Risk

  • Individuals with a family history of pancreatic cancer or known genetic mutations (such as BRCA2, CDKN2A, or Peutz-Jeghers syndrome) are at higher risk10,11
  • MRI is often used for surveillance in these groups, as it can detect early or subtle changes before symptoms develop12.

Clarifying Pancreatic Cysts

  • MRI is superior to other imaging techniques for characterising pancreatic cysts. It helps distinguish between benign, premalignant, and malignant cysts, guiding decisions about whether to monitor, biopsy, or surgically remove the lesion13.

Monitoring Treatment Response

  • For patients undergoing neoadjuvant chemotherapy or radiotherapy for pancreatic cancer, MRI (especially with diffusion-weighted imaging) is valuable for monitoring how well the tumour is responding to treatment and for planning potential surgery14,15.

How To Prepare for Your Pancreas MRI

Here are a few tips to help you prepare for your MRI16:

  • Take your usual medications and eat normally, unless instructed to fast for specific MRI protocols. Fasting is not always required however17. Avoid heavy caffeine intake and stay hydrated.
  • Inform staff about any metal implants or devices, and bring safety cards for “MR-Conditional” implants, such as pacemakers or aneurysm clips.
  • Remove all metal items, including jewellery, hairpins, dental plates, and transdermal patches with foil, to prevent image distortion.
  • Bring your referral, prior brain images, and insurance pre-authorisation to avoid delays.
  • Wear comfortable, metal-free clothing; ask about earplugs, music, or mirror goggles if you’re claustrophobic.
  • If contrast is planned, fast for 4–6 hours prior to the procedure. Inform staff about any kidney issues or past reactions to contrast agents, as safer alternatives may be available.
  • Arrange an escort home if you need sedation for claustrophobia.

You can read more about preparation for Ezra’s Full Body Scan here.

What Happens During the Pancreas Scan?

Upon arrival for your MRI, you will need to check in and complete a screening form. This will allow you to confirm the presence of implants, allergies, and whether you might need any anxiety medication.

During the scan, you will lie down on a sliding table. A dedicated surface or phased-array coil is typically placed over the limb or region of interest18. Your head will be nestled in a small cushion that will keep you still. The scan typically lasts 30-45 minutes of actual “table time”, during which the technician may acquire multiple sequences (settings), including T1-, T2-, and DWI/ADC weighted images, and often MRCP sequences to visualise the pancreatic and bile ducts in detail19,20. Other sequences that can be included are fat-suppressed T1-weighted imaging, elastography, secretin-enhanced MRCP, and extracellular volume quantification.

You may be asked to hold your breath for short periods during the scan to minimise motion and improve image clarity.

You may also be given pineapple juice or ferumoxsil, which act as negative contrast agents to improve the visibility of the bile and pancreatic ducts21,22.

You’ll hear a series of loud knocking or tapping sounds as the MRI machine works. This is completely normal. The scan usually takes about 20 to 45 minutes, and you’ll be offered earplugs or headphones to make the experience more comfortable. 

You’ll stay in touch with the team via a two-way intercom and a squeeze bulb, allowing you to communicate or pause the scan if needed. If contrast is required, it’s injected halfway through, possibly causing a brief cool sensation. After the final sequence, the coil is removed, and you’re free to go. 

At Ezra, our Full Body Plus scan takes around 60 minutes total, with 45 minutes of table time. Earplugs or headphones are available.

MRI Safety, Risks, & Side-Effects

MRI is generally considered very safe when proper screening and protocols are followed, but certain risks and side effects should be understood:

  • Metal and implants: The strong 3-Tesla magnet can pull or heat older pacemakers, aneurysm clips, or metal fragments23. Most modern “MR-Conditional” devices (like cochlear implants or pain pumps) are safe after screening, but all implants must be checked before scanning24.
  • Gadolinium contrast: Macrocyclic gadolinium agents (e.g., gadobutrol) have an extremely low risk of allergic reactions or nephrogenic systemic fibrosis (NSF) when kidneys are healthy25. However, gadolinium can accumulate in tissues, and rare side effects such as headaches or skin changes have been reported. Many centres now offer contrast-free alternatives for routine follow-up26. You can read more about gadolinium contrast side effects here.
  • Incidental findings: Pancreatic cysts are the most frequent incidental findings, seen in up to 13.5-19.9% of abdominal MRI studies27,28.
  • Claustrophobia: Anxiety inside the scanner is common. Wide-bore scanners, music, mirror goggles, or a single dose of oral sedative can help alleviate symptoms. Open MRI is an option if image detail can be sacrificed.
  • Zero Ionising Radiation: MRI uses magnetic fields and radio waves, not X-rays, so there is no ionising radiation exposure, making it safer for repeated scans compared to CT scans29.
  • Minor Sensations: Expect loud knocking, mild table vibration, and a brief cool flush if contrast is injected. Rare side effects include headaches, fatigue, or mild skin heating.

A deeper dive into possible side effects (such as heat, headaches, and gadolinium deposition) is available in our full guide.

At Ezra, we employ a contrast-free approach using wide-bore T3 machines to deliver a comfortable scanning experience.

Terms You Might See in Your MRI Report (And What They Mean)

MRI reports for the pancreas often use technical language. Here’s a guide to some common terms and what they mean for your diagnosis and treatment:

  • Hypo-enhancing mass: The mass takes up less contrast than the surrounding pancreas tissue30. This is typical of pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.
  • Diffusion restriction/low ADC: An area where water movement is limited, strongly suggesting malignancy31
  • Double-duct sign: Both the pancreatic and bile ducts are enlarged, a classic sign of a tumour in the head of the pancreas32.
  • SMA encasement ≥180°: The tumour wraps around at least half of the superior mesenteric artery, usually meaning it can’t be surgically removed33.
  • EPNI (extrapancreatic neural invasion): The cancer has spread along nerves outside the pancreas, which increases the risk of recurrence34.
  • Side branch IPMN (intraductal papillary mucinous neoplasm): A cyst in the side branches of the pancreatic duct, which may need surgery if it contains a nodule 5 mm or larger35.
  • Cystic component/mural nodule: A cyst with a solid lump inside, which raises suspicion for cancer36.
  • MRCP cut-off at the neck: The pancreatic duct is abruptly blocked at the neck of the pancreas, pinpointing the likely location of a tumour37.

Ezra provides a radiologist-reviewed report in a non-technical and easy-to-understand format on your dashboard.

After the MRI Scan

After the MRI scan, you will be free to go home and continue with your day without any precautions38. If you received a sedative, you will need another person to pick you up. You will also not be able to drive, consume alcohol or operate heavy machinery 24 hours after the sedative. 

A team of experts will review your results and determine whether a follow-up is necessary and recommend the appropriate treatment if needed. If abnormalities are found, you may undergo ongoing monitoring every 2-3 months to track recurrence. You can receive support in the form of counselling and advice on how to handle aspects like claustrophobia. 

If you have a scan with us here at Ezra, you will receive your report within five to seven days and have the option to discuss it with a medical practitioner. You can also access your scan images through the online portal.

What MRI Can Show About Pancreatic Cancer

Size and Exact Location of the Primary Mass

MRI provides highly detailed images, allowing radiologists to measure the size and pinpoint the precise location of a pancreatic tumour down to the millimetre. This accuracy is crucial for surgical planning and assessing whether the tumour is operable39

Vascular Invasion

MRI can reveal if the tumour has invaded nearby blood vessels, such as the superior mesenteric artery (SMA) or portal vein40. If the tumour wraps around these vessels by 180° or more, surgery may require vascular grafting or may be contraindicated altogether, as this degree of invasion often means the cancer is unresectable.

Ductal Changes

Using MRCP sequences, MRI can assess the calibre of the pancreatic and bile ducts, detect abrupt ductal cut-offs (which can indicate tumour location), and identify side-branch communications37,41. These findings help diagnose and characterise both cancer and its precursor lesions.

Diffusion Restriction and ADC Values

MRI with diffusion-weighted imaging can show areas where water movement is restricted and provide apparent diffusion coefficient (ADC) values31. Low ADC values often correlate with high tumour cellularity and aggressiveness, helping to distinguish malignant from benign tissue.

Peripancreatic Lymph-Node Status and Subtle Metastases

MRI is sensitive for detecting enlarged or abnormal lymph nodes around the pancreas and can identify subtle liver or peritoneal metastases that may not be visible on CT scans42. This ability is vital for accurate staging and treatment planning.

Neural-Plexus Spread

MRI can visualise tumour spread along the celiac or SMA nerve plexuses43. Detecting neural invasion is important because it increases the risk of local recurrence after treatment and may influence surgical decision-making.

Ezra utilises DWI as part of our whole-body MRI scans and artificial intelligence (AI) to enhance MRI images and convert radiology reports into layman's term translations.

Types of Pancreatic Tumours and How They Look on MRI

  • Pancreatic ductal adenocarcinoma (PDAC) typically appears iso- to hypo-intense on T1 and T2 MRI sequences, with strong diffusion restriction and low ADC values44. It is usually hypovascular on dynamic contrast imaging, meaning it enhances less than normal pancreatic tissue. PDAC often causes ductal dilatation and abrupt cutoff, and may invade nearby vessels and tissues30.
  • Neuroendocrine tumours (NETs) are characteristically hyperintense on T2-weighted images and show intense, early arterial enhancement, sometimes referred to as the “light-bulb” sign45,46. These tumours are often well-defined and do not usually cause ductal dilation. They can be multifocal, especially in patients with genetic predispositions.
Figure 1: A 54-year-old man with pancreatic neuroendocrine carcinoma. MRI with fat-suppressed LAVA T1- and T2-weighted imaging. Adapted from: Source. Image obtained under the Creative Commons License.
  • Mucinous cystic neoplasms (MCN) present as large, macrocystic lesions with internal septations and sometimes peripheral calcifications47. They may contain an enhancing mural nodule, which raises suspicion for malignancy. MCNs almost always occur in women and are usually found in the body or tail of the pancreas48.
  • Intraductal papillary mucinous neoplasms (IPMN) are seen as dilated main or side-branch ducts on MRI, with MRCP often showing a “fish-eye” or “bunch-of-grapes” appearance49. These lesions can communicate with the main pancreatic duct and may contain mural nodules. The risk of malignancy depends on the type and features of the IPMN.
Figure 2: Branch duct IPMN. (A) Axial T2-weighted image demonstrates a multilocular cystic lesion in the pancreatic head (arrowhead). (B) Volume rendered image from MRCP demonstrates the bunch of grape appearance (arrow) with duct communication (arrowhead), confirming the diagnosis of BD-IPMN. (C) Volume rendered MRCP from another patient demonstrates numerous branch duct IPMNs throughout the gland (arrowheads). Adapted from Source. Image obtained under the Creative Commons License.
  • Solid pseudopapillary neoplasms (SPN) appear as heterogeneous masses with both solid and cystic components, surrounded by a thick capsule50. They demonstrate gradual progressive enhancement after contrast administration. SPNs predominantly affect young women and generally have low malignant potential51.
  • Metastases to the pancreas, such as those from renal cell carcinoma (RCC), often present as hyper-vascular masses with strong arterial enhancement and can be multifocal52. These lesions may appear hyperintense on certain MRI sequences. A history of another primary cancer, particularly RCC, is a key clue to their diagnosis.

Ezra screens for over 500 conditions and 13 organs, including pancreas. 

Types of MRI Scans Used in Pancreatic Cancer Detection

There are multiple types of MRI scans, all using different methods to give a better visualisation of pancreatic tumours. 

  • High-Resolution T2-Weighted Imaging: This scan is very sensitive to fluids and highlights even tiny cysts or changes in the ducts, making it easier to spot and tell apart harmless cysts from those that could be cancerous53.
  • Diffusion-Weighted Imaging (DWI) with ADC Maps: This technique shows how water moves inside the pancreas; cancerous tumours usually block this movement, so they stand out clearly even when they’re small54.
  • Magnetic Resonance Cholangiopancreatography (MRCP): MRCP creates detailed images of the bile and pancreatic ducts, helping doctors spot blockages, abnormal shapes, or clusters of cysts without needing an invasive procedure55.
  • Secretin-Enhanced MRCP: A small hormone injection makes the ducts temporarily widen, allowing doctors to see subtle problems or test how well the pancreas is working56.
  • Intravoxel Incoherent Motion (IVIM) / Dynamic Perfusion MRI: These advanced scans look at both water movement and blood flow in the pancreas, helping to tell the difference between active tumour tissue and scar tissue after treatment57.
  • MR Elastography (MRE): This scan gently vibrates the pancreas to measure how stiff it is; cancerous areas tend to be much stiffer than healthy tissue, helping doctors tell different types of tumours apart58.

Ezra uses whole-body DWI imaging to get a full picture of the body and catch any potential abnormalities.

MRI vs. Other Imaging Tests for Pancreatic Cancer Detection

Modality Strengths Limitations
Pancreas MRI (multiphase T1 ± DWI) TExcellent for detecting solid tumours ≥1 cm, DWI flags most pancreatic cancers and liver metastases, no ionising radiation exposure. Lacks detailed duct images so early duct cut-offs or small IPMN may be missed, vascular invasion less certain without contrast, diffusion changes can overlap with pancreatitis.
MRCP (heavily T2- weighted, ± secretin) Non-invasive “virtual ERCP” mapping of ducts, detects duct-centric tumours before a mass forms, useful for cystic lesion assessment and surgical planning. Less effective for solid tumours unless combined with MRI, requires breath-holding; image artifacts possible with ascites or stents, adds time and not standard in whole-body scans.
CT (multiphase pancreas protocol) Fast and widely available, excellent for mapping arteries and veins. Can miss small (under 2 cm) or iso-attenuating tumours, involving radiation exposure.
Endoscopic ultrasound (EUS ± FNA) Highest resolution for pancreas, allows for biopsy of suspicious areas. Invasive, requires sedation and skilled operator, limited for detecting distant spread, risks include pancreatitis, bleeding, and infection.
PET-CT (¹⁸F-FDG) Whole body scan for hidden nodal or peritoneal disease which is useful for staging and recurrence. Expensive, higher radiation dose, small or mucinous tumours may not show up (“FDG-cold”), false positives with inflammation or infection.
Contrast-enhanced ultrasound (CEUS) Bedside, repeatable and real-time vascular imaging for liver metastases, no radiation or kidney-toxic contrast. Pancreatic view limited by bowel gas or obesity, operator-dependent, not suitable for full pancreas staging.

MRI Scan Cost

Ezra’s Full Body Plus MRI scan in the UK costs £2,695 and is currently available at their partner clinic in Marylebone, London, with more locations planned in the future.

No referral is required, so you can book your scan directly without first consulting a GP or specialist.

Most people pay out-of-pocket, as insurance typically does not cover self-referred scans, but you may be able to seek reimbursement depending on your policy. 

Frequently Asked Questions

Can MRI miss pancreatic cancer?

Yes, MRI can occasionally miss very small tumours or those that closely mimic benign changes, especially in early or subtle changes.

Is MRI enough to diagnose pancreatic cancer?

MRI is highly sensitive but a definitive diagnosis usually requires a tissue biopsy in addition to imaging.

Which is better, MRCP or MRI?

MRCP is a specialised MRI technique focused on imaging the pancreatic and bile ducts, while standard MRI provides broader information about the pancreas and surrounding tissues; both are often used together for a comprehensive assessment.

MRCP vs. ERCP

MRCP is non-invasive and excellent for visualising ducts, but ERCP allows for direct intervention and biopsy, though it carries more risk.

Key Takeaways

  • Pancreatic MRI with MRCP is a powerful, non-invasive tool that can detect tumours as small as a few millimetres, often before they block ducts or blood vessels. This early detection is crucial for improving the chances of successful surgical treatment.
  • Advanced MRI sequences, such as Diffusion-Weighted Imaging (DWI) and secretin-enhanced MRCP, reveal subtle changes in the pancreas that may be invisible on CT scans. These techniques can identify early or hidden cancers, giving more patients the opportunity for curative surgery.
  • For those with a genetic or family history of pancreatic cancer, annual MRI/MRCP screening should be considered. Early detection at stage I can triple survival odds compared to later stages, making regular imaging especially important for high-risk individuals.

Ready to take proactive steps for your health? Book an Ezra full-body MRI today to detect any issues early and put you on the road to long-term health. Our yearly scan screens for potential cancers early, using AI to enhance the process, making it more efficient and affordable.

Our MRI scan is designed to help detect cancer early without harmful radiation.
Book Scan Icon
It's quick and easy to book
Schedule your scan online at one of our locations nationwide.
Complete Scan Icon
Medical questionnaire
Fill out a quick online form to let us know about your medical history.
Get Scanned
Get your Ezra Full Body MRI Scan — it takes as little as 30 minutes and screens for potential cancer in up to 13 organs and 500+ conditions.
Walk Icon
A bespoke medical report
Your images are reviewed by board certified radiologists and our Clinical Team will deliver your Ezra Report within 5-7 days.

References

1. Pancreatic cancer statistics. Pancreatic Cancer UK. Accessed July 10, 2025. https://www.pancreaticcancer.org.uk/what-we-do/media-centre/pancreatic-cancer-statistics/

2. Action PC. Pancreatic Cancer Prognosis & Survival | Pancreatic Cancer Awareness |. Pancreatic Cancer Action. Accessed July 10, 2025. https://pancreaticcanceraction.org/about-pancreatic-cancer/pancreatic-cancer-prognosis-and-survival/

3. Radiology (ACR) RS of NA (RSNA) and AC of. MRCP (MR Cholangiopancreatography). Radiologyinfo.org. Accessed July 10, 2025. https://www.radiologyinfo.org/en/info/mrcp

4. Chu LC, Goggins MG, Fishman EK. Diagnosis and Detection of Pancreatic Cancer. Cancer J. 2017;23(6):333-342. doi:10.1097/PPO.0000000000000290

5. Flammia F, Fusco R, Triggiani S, et al. Risk Assessment and Radiomics Analysis in Magnetic Resonance Imaging of Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMN). Cancer Control. 2024;31:10732748241263644. doi:10.1177/10732748241263644

6. Schaible J, Grenacher L, Stroszczynski C, et al. The chronic pancreatitis (CP) Type Cambridge 2 as a cause of unclear upper abdominal pain: a radiologically underestimated diagnosis. Rofo. 2024;196(12):1262-1269. doi:10.1055/a-2275-0946

7. Frank RC, Shim B, Lo T, et al. Pancreatic Cancer Screening in New-onset and Deteriorating Diabetes: Preliminary Results From the PANDOME Study. The Journal of Clinical Endocrinology & Metabolism. Published online May 29, 2025:dgaf319. doi:10.1210/clinem/dgaf319

8. Pannala R, Basu A, Petersen GM, et al. New-onset Diabetes: A Potential Clue to the Early Diagnosis of Pancreatic Cancer. Lancet Oncol. 2009;10(1):88-95. doi:10.1016/S1470-2045(08)70337-1

9. Krishna N, Tummala P, Reddy AV, et al. Dilation of both pancreatic duct and the common bile duct on computed tomography and magnetic resonance imaging scans in patients with or without obstructive jaundice. Pancreas. 2012;41(5):767-772. doi:10.1097/MPA.0b013e31823ba536

10. Lowe T, Deluca J, Abenavoli L, et al. Pancreatic Cancer and the Family Connection: The Role of Advanced Practitioners in Screening and Educating Genetically At-Risk Individuals. J Adv Pract Oncol. 2023;14(6):533-539. doi:10.6004/jadpro.2023.14.6.6

11. Welinsky S, Lucas AL. Familial Pancreatic Cancer and the Future of Directed Screening. Gut Liver. 2017;11(6):761-770. doi:10.5009/gnl16414

12. Overbeek KA, Levink IJM, Koopmann BDM, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71(6):1152-1160. doi:10.1136/gutjnl-2020-323611

13. Halankar J, Jhaveri K, Metser U. Cystic lesions of the pancreatico-biliary tree: A schematic MRI approach. Indian J Radiol Imaging. 2017;27(2):167-176. doi:10.4103/ijri.IJRI_226_16

14. Hussien N, Hussien RS, Saad DHA, et al. The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer. Front Oncol. 2022;11:796317. doi:10.3389/fonc.2021.796317

15. Zhang Y, Huang ZX, Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. World J Gastroenterol. 2021;27(22):3037-3049. doi:10.3748/wjg.v27.i22.3037

16. Radiology (ACR) RS of NA (RSNA) and AC of. Magnetic Resonance Imaging (MRI) - Head. Radiologyinfo.org. Accessed July 3, 2025. https://www.radiologyinfo.org/en/info/mri-brain

17. Williams JM, Hilmes MA, Archer B, et al. Repeatability and Reproducibility of Pancreas Volume Measurements Using MRI. Sci Rep. 2020;10:4767. doi:10.1038/s41598-020-61759-9

18. Gruber B, Froeling M, Leiner T, et al. RF coils: A practical guide for nonphysicists. J Magn Reson Imaging. 2018;48(3):590-604. doi:10.1002/jmri.26187

19. Sandrasegaran K, Lin C, Akisik FM, et al. State-of-the-Art Pancreatic MRI. American Journal of Roentgenology. 2010;195(1):42-53. doi:10.2214/AJR.10.4421

20. Hill DV, Tirkes T. Advanced MR Imaging of the Pancreas. Magn Reson Imaging Clin N Am. 2020;28(3):353-367. doi:10.1016/j.mric.2020.03.003

21. Leung K. Ferumoxsil. In: Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information (US); 2004. Accessed July 10, 2025. http://www.ncbi.nlm.nih.gov/books/NBK22994/

22. Mohabir S, Pitcher RD, Perumal R, et al. The efficacy of pineapple juice as a negative oral contrast agent in magnetic resonance cholangiopancreatography. SA J Radiol. 2020;24(1):1875. doi:10.4102/sajr.v24i1.1875

23. Gill A, Shellock FG. Assessment of MRI issues at 3-Tesla for metallic surgical implants: findings applied to 61 additional skin closure staples and vessel ligation clips. J Cardiovasc Magn Reson. 2012;14(1):3. doi:10.1186/1532-429X-14-3

24. Potential Hazards and Risks. UCSF Radiology. January 20, 2016. Accessed March 14, 2025. https://radiology.ucsf.edu/patient-care/patient-safety/mri/potential-hazards-risks

25. Costello JR, Kalb B, Martin DR. Incidence and Risk Factors for Gadolinium-Based Contrast Agent Immediate Reactions. Top Magn Reson Imaging. 2016;25(6):257-263. doi:10.1097/RMR.0000000000000109

26. McDonald RJ, McDonald JS, Kallmes DF, et al. Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities. Radiology. 2017;285(2):546-554. doi:10.1148/radiol.2017161595

27. Gore RM, Wenzke DR, Thakrar KH, et al. The incidental cystic pancreas mass: a practical approach. Cancer Imaging. 2012;12(2):414-421. doi:10.1102/1470-7330.2012.9054

28. Kruse E D, Paulson E K. The Incidental Pancreatic Cyst: When to Worry About Cancer. Korean Journal of Radiology. 2024;25(6):559-564. doi:10.3348/kjr.2024.0085

29. Mall MA, Stahl M, Graeber SY, et al. Early detection and sensitive monitoring of CF lung disease: Prospects of improved and safer imaging. Pediatr Pulmonol. 2016;51(S44):S49-S60. doi:10.1002/ppul.23537

30. Miller FH, Lopes Vendrami C, Hammond NA, et al. Pancreatic Cancer and Its Mimics. RadioGraphics. 2023;43(11):e230054. doi:10.1148/rg.230054

31. Abdelgawad EA, Rahim AMA, Rahman A shimaa MA. Can diffusion-weighted MRI replace conventional contrast enhanced MRI in the differentiation between benign and malignant pancreatic masses? The Egyptian Journal of Radiology and Nuclear Medicine. 2018;49(4):899-902. doi:10.1016/j.ejrnm.2018.07.014

32. Oterdoom LH, van Weyenberg SJB, de Boer NKH. Double-duct sign: do not forget the gallstones. J Gastrointestin Liver Dis. 2013;22(4):447-450.

33. Mullapudi B, Hawkes PJ, Patel A, et al. Borderline Resectable Pancreatic Cancer. Indian J Surg Oncol. 2015;6(1):63-68. doi:10.1007/s13193-014-0374-8

34. Levy MJ, Topazian M, Keeney G, et al. Preoperative Diagnosis of Extrapancreatic Neural Invasion in Pancreatic Cancer. Clinical Gastroenterology and Hepatology. 2006;4(12):1479-1482. doi:10.1016/j.cgh.2006.08.012

35. Boraschi P, Tarantini G, Donati F, et al. Side-branch intraductal papillary mucinous neoplasms of the pancreas: outcome of MR imaging surveillance over a 10 years follow-up. Eur J Radiol Open. 2020;7:100250. doi:10.1016/j.ejro.2020.100250

36. Zhong N, Zhang L, Takahashi N, et al. Histologic and Imaging Features of Mural Nodules in Mucinous Pancreatic Cysts. Clinical Gastroenterology and Hepatology. 2012;10(2):192-198.e2. doi:10.1016/j.cgh.2011.09.029

37. Johnston A, Serhal A, Lopes Vendrami C, et al. The abrupt pancreatic duct cutoff sign on MDCT and MRI. Abdom Radiol (NY). 2020;45(8):2476-2484. doi:10.1007/s00261-020-02582-8

38. MRI scan. NHS inform. Accessed July 3, 2025. https://www.nhsinform.scot/tests-and-treatments/scans-and-x-rays/mri-scan/

39. Michallek F, Haouari MA, Dana O, et al. Fractal analysis improves tumour size measurement on computed tomography in pancreatic ductal adenocarcinoma: comparison with gross pathology and multi-parametric MRI. Eur Radiol. 2022;32(8):5053-5063. doi:10.1007/s00330-022-08631-8

40. Zhou X, Xu D, Wang M, et al. Preoperative assessment of peripheral vascular invasion of pancreatic ductal adenocarcinoma based on high-resolution MRI. BMC Cancer. 2023;23:1092. doi:10.1186/s12885-023-11451-8

41. Balcı C. MRI assessment of chronic pancreatitis. Diagn Interv Radiol. 2011;17(3):249-254. doi:10.4261/1305-3825.DIR.3889-10.0

42. Luo YG, Wu M, Chen HG. Retrospective analysis of pathological types and imaging features in pancreatic cancer: A comprehensive study. World J Gastrointest Oncol. 2025;17(1):99153. doi:10.4251/wjgo.v17.i1.99153

43. Liu YL, Zhu HB, Chen ML, et al. Prediction of the lymphatic, microvascular, and perineural invasion of pancreatic neuroendocrine tumors using preoperative magnetic resonance imaging. World J Gastrointest Surg. 2023;15(12):2809-2819. doi:10.4240/wjgs.v15.i12.2809

44. Miller FH, Rini NJ, Keppke AL. MRI of Adenocarcinoma of the Pancreas. American Journal of Roentgenology. 2006;187(4):W365-W374. doi:10.2214/AJR.05.0875

45. Guo C, Chen X, Wang Z, et al. Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging. Oncotarget. 2017;8(26):42962-42973. doi:10.18632/oncotarget.17309

46. Manfredi R, Bonatti M, Mantovani W, et al. Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour. Eur Radiol. 2013;23(11):3029-3039. doi:10.1007/s00330-013-2929-4

47. Hu F, Hu Y, Wang D, et al. Cystic Neoplasms of the Pancreas: Differential Diagnosis and Radiology Correlation. Front Oncol. 2022;12:860740. doi:10.3389/fonc.2022.860740

48. Roalsø MTT, Hughes DL, Larsson P, et al. Mucinous cystic neoplasia (MCN) of the pancreas: systematic review and meta-analysis of sex differences in prevalence and malignancy risk between males and females. Chin Clin Oncol. 2025;14(2):19. doi:10.21037/cco-24-124

49. Quingalahua E, Al-Hawary MM, Machicado JD. The Role of Magnetic Resonance Imaging (MRI) in the Diagnosis of Pancreatic Cystic Lesions (PCLs). Diagnostics (Basel). 2023;13(4):585. doi:10.3390/diagnostics13040585

50. Kovac JD, Djikic-Rom A, Bogdanovic A, et al. The Role of MRI in the Diagnosis of Solid Pseudopapillary Neoplasm of the Pancreas and Its Mimickers: A Case-Based Review with Emphasis on Differential Diagnosis. Diagnostics (Basel). 2023;13(6):1074. doi:10.3390/diagnostics13061074

51. Wu J, Mao Y, Jiang Y, et al. Sex differences in solid pseudopapillary neoplasm of the pancreas: A population‐based study. Cancer Med. 2020;9(16):6030-6041. doi:10.1002/cam4.3180

52. Sikka A, Adam SZ, Wood C, et al. Magnetic resonance imaging of pancreatic metastases from renal cell carcinoma. Clinical Imaging. 2015;39(6):945-953. doi:10.1016/j.clinimag.2015.07.012

53. Zhang XM, Mitchell DG, Dohke M, et al. Pancreatic cysts: depiction on single-shot fast spin-echo MR images. Radiology. 2002;223(2):547-553. doi:10.1148/radiol.2232010815

54. ŞAHAN MH, ÖZDEMİR A, ASAL N, et al. Pancreas and kidney changes in type 2 diabetes patients: the role of diffusion-weighted imaging. Turk J Med Sci. 2021;51(3):1289-1295. doi:10.3906/sag-2011-176

55. Zhang T, Shi X, Li J, et al. Horizontal duodenal papilla is associated with a special spectrum of pancreaticobiliary diseases: a retrospective magnetic resonance cholangiopancreatography-based study. Gastroenterol Rep (Oxf). 2024;12:goae059. doi:10.1093/gastro/goae059

56. Sanyal R, Stevens T, Novak E, et al. Secretin-enhanced MRCP: review of technique and application with proposal for quantification of exocrine function. AJR Am J Roentgenol. 2012;198(1):124-132. doi:10.2214/AJR.10.5713

57. Liu X, Wang YF, Qi XH, et al. Reproducibility study of intravoxel incoherent motion and apparent diffusion coefficient parameters in normal pancreas. World J Gastrointest Surg. 2024;16(7):2031-2039. doi:10.4240/wjgs.v16.i7.2031

58. Steinkohl E, Bertoli D, Hansen TM, et al. Practical and clinical applications of pancreatic magnetic resonance elastography: a systematic review. Abdom Radiol (NY). 2021;46(10):4744-4764. doi:10.1007/s00261-021-03143-3